Key Highlights
- H1 2026 underlying EBITDA rose 16.4% to £96.7m, with Margin up about 80bps to 10.1%.
- Revenue increased 6.7% to £954.3m on 2.3% higher volumes; underlying pre-tax profit reached £12.7m.
- Full-year outlook upgraded to slightly ahead of forecasts, with EBITDA guidance around £162m; shares jumped roughly 13%.
- Net Debt rose to £671.3m (from £575.0m at end-2025) with covenant Leverage near 4.9x; FY leverage guided to 4.0x-4.35x.
- Acrylate Monomers sale expected to close by 30 September 2026; three further divestments could raise £150m-£200m.
Synthomer (LSE:SYNT), one of the world's larger producers of latices and speciality polymers, has spent the past two years fighting on two fronts: rebuilding profitability after a brutal chemicals downturn, and cutting a debt pile that ballooned through the cycle. Its half-year results, published on 5 August 2026, offered the clearest evidence yet that the first battle is being won.
The market reaction was emphatic, with the shares jumping around 13% on the day as management raised full-year guidance on the back of expanding margins and higher volumes. But the second front, leverage, remains stubborn: net debt actually rose over the first half, a reminder that the turnaround is still a work in progress rather than a completed job.
Latest Development
For the six months to 30 June 2026, Synthomer reported underlying EBITDA from continuing operations of £96.7 million, up 16.4% year on year, and said it now expects full-year results to come in slightly ahead of prevailing market forecasts. Management guided to full-year EBITDA of roughly £162 million and to positive free Cash Flow in the second half.
Crucially, the company flagged that not all of the improvement is durable: it attributed around £8 million of the EBITDA uplift to recurring self-help and strategic initiatives, but roughly £6 million to temporary benefits from Supply disruptions linked to geopolitical conflict. Alongside the results, Synthomer confirmed it was pressing ahead with the sale of its Acrylate Monomers business, expected to close by 30 September 2026, plus three further divestments earmarked to reduce debt.
The Numbers
Group Revenue from continuing operations rose 6.7% to £954.3 million, with sales volumes up 2.3% and pricing discipline supporting the top line. The underlying EBITDA margin expanded about 80 basis points to 10.1%, from 9.3% a year earlier, while underlying EBIT climbed 41.7% to £48.6 million. Underlying pre-tax profit reached £12.7 million, a marked improvement on the £1.3 million reported in the first half of 2025, and underlying Earnings Per Share swung to 21.5 pence from a 3.6 pence loss.
The Balance Sheet is where caution is warranted. Net debt increased to £671.3 million at 30 June 2026, from £575.0 million at the end of 2025, reflecting negative first-half free cash flow of about £80.8 million driven by seasonal working capital. Covenant leverage stood at roughly 4.9x, comfortably inside the relaxed 6.25x December 2026 covenant, and management is guiding to a full-year leverage range of 4.0x to 4.35x as second-half cash generation and disposal proceeds arrive.
The Investment Story
Synthomer sells water-based polymers, dispersions and functional additives into coatings, construction, adhesives, and health and protection markets, giving it broad but cyclical exposure to industrial and consumer demand. After acquiring the adhesive-technologies Business that reshaped the group, and then enduring a savage destocking cycle, the strategy has narrowed to simplification: shed non-core, commodity-like assets, concentrate on higher-margin speciality lines and use the proceeds to deleverage.
The bull case is that the group is emerging from the trough with structurally better margins, a leaner portfolio and pricing power in differentiated products. Gross margin has improved around 190 basis points over the past year and roughly 600 basis points over four years, suggesting the self-help programme is delivering. If disposals land at good prices and end-markets keep recovering, the Equity offers geared exposure to both earnings recovery and balance-sheet repair.
What Could Drive the Shares?
The near-term swing factors are execution on disposals and the trajectory of free cash flow. Completion of the Acrylate Monomers sale and progress on the three further divestments would provide hard evidence that net debt is falling, which is the single biggest overhang on the rating.
Beyond that, sustained Volume recovery in coatings and construction, continued margin expansion from strategic initiatives, and delivery on the roughly £162 million full-year EBITDA guide would support the case. A clearer path back to dividends, once leverage is under control, could also re-rate the shares over time.
Risks Investors Should Watch
Leverage remains the dominant risk. Net debt rose over the first half, and although covenants have been relaxed, the group needs second-half cash generation and disposal proceeds to materialise to hit its 4.0x to 4.35x target. A slip in either could quickly revive balance-sheet concerns.
The results also flagged that part of the EBITDA improvement was temporary, tied to competitor supply disruptions that may reverse. Broader risks include weak or volatile Demand in cyclical end-markets, raw-material and energy cost swings, foreign-exchange movements across a global footprint, and the execution risk inherent in selling Assets into an uncertain chemicals market. The Dividend remains suspended.
What Happens Next?
The most immediate milestone is completion of the Acrylate Monomers disposal, targeted by 30 September 2026, which will test management's deleveraging narrative. Progress on the three additional divestments will be watched closely through the second half.
Investors will then look to the full-year 2026 results in early 2027 to confirm whether Synthomer delivered on its upgraded roughly £162 million EBITDA guidance, generated the promised positive second-half free cash flow, and brought leverage down into the guided range.
Bottom Line
Synthomer (LSE:SYNT)'s half-year results marked a genuine inflection in profitability: margins are rebuilding, volumes are growing and management felt confident enough to lift full-year guidance, prompting a sharp share-price rally. The bull case is a leaner, higher-margin speciality-chemicals group emerging from a deep downturn with real operating momentum. The counterweight is a balance sheet that saw net debt rise over the half and leverage near 4.9x, leaving the investment case dependent on disposals and second-half cash flow. The central debate is whether improving earnings can outrun the debt fast enough to complete the turnaround.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...